Alzheon raises $100M; Regeneron ends mid-stage trial

Plus, news about Genmab, BioNTech, Bristol Myers Squibb, BridgeBio, Junshi, Tevogen, Actuate, GSK, Ochre Bio, Evotec and ProKidney:

Alzheon raises $100M Series E: The company’s lead program is currently in a Phase 3 study for early Alzheimer’s disease that’s expected to be completed this year. Alzheon Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

Advertise With Biotech Networks